Use of vagal nerve stimulation as a treatment for @entity302 in XXXX .

@entity410 @entity235 @entity2080 @entity302 @entity1167 @entity1168 @entity4820 @entity386
OBJECTIVE: To evaluate safety and efficacy of vagal nerve stimulation in @entity235 with @entity302 . DESIGN: Placebo-controlled, double-masked, crossover study. ANIMALS: 10 @entity235 with poorly controlled @entity410 . PROCEDURE: A programmable pacemaker-like device designed to deliver intermittent stimulation to the left cervical trunk of the vagus was surgically implanted in each @entity235 . @entity235 were assigned randomly to two 13-week test periods, 1 with nerve stimulation and 1 without nerve stimulation. Owners recorded data on @entity410 frequency, duration, and intensity, as well as adverse effects. RESULTS: No significant difference in @entity410 frequency, duration, or severity was detected between overall 13-week treatment and control periods. During the final 4 weeks of the treatment period, a significant decrease in mean @entity410 frequency (34.4%) was detected, compared with the control period. Complications included transient @entity1168 , @entity1167 , and @entity386 during intraoperative device testing, and @entity2080 formation, subcutaneous migration of the generator, and transient @entity4820 during the 14-day period between surgery and suture removal. No adverse effects of stimulation were detected, and most owners were satisfied with the treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Vagal nerve stimulation is a potentially safe approach to @entity410 control that appears to be efficacious in certain @entity235 and should be considered a possible treatment option when antiepileptic medications are ineffective.
